2017 Gastrointestinal Cancers Symposium Press Program to Highlight New Treatment Insights and Strategies

For immediate release
December 8, 2016


Alise Fisher

ALEXANDRIA, Va. – Co-sponsors of the 2017 Gastrointestinal Cancers Symposium announced today three abstracts to be featured in the meeting’s official Press Program. Researchers will present the findings of these studies in an embargoed presscast for reporters, taking place Tuesday, January 17, 2017, from 12:00 noon – 1:30 PM (ET).

The following studies will be highlighted during the presscast:

  • Results from a phase II trial exploring whether use of PET scans to guide pre-op treatment decisions improves outcomes for patients with esophageal cancer (Abstract 1).
  • An analysis of outcomes for patients with rectal cancer from the International Watch & Wait database for rectal cancer (Abstract 521).
  • Results from a study examining the association between physical activity and advanced colorectal cancer survival (Abstract 659).

The 2017 Gastrointestinal Cancers Symposium will take place January 19-21 at the Moscone West Building in San Francisco, California. Abstracts presented at the Symposium will discuss the latest science in cancers of the pancreas, small bowel, and hepatobiliary tract; colon and rectum; and esophagus and stomach. On-site facilities for reporters will include a working newsroom and access to leading experts in gastrointestinal cancers.

Visit the 2017 Gastrointestinal Cancers Symposium Media Resource Center for instructions on how to register for the meeting, as well as how to participate in the presscast.

# # #

About the Symposium:
Four leading medical specialty societies co-sponsor the Symposium: the American Gastroenterological Association (AGA) Institute, the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Surgical Oncology (SSO). Information about the cosponsors is available on the Symposium website.

About ASCO: 

Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 40,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org, explore patient education resources at www.Cancer.Net, and follow us on FacebookTwitterLinkedIn, and YouTube.